Furthermore, mTOR inhibitors Everolimus and Temsirolimus have shown promising results as adjunctive agents together with traditional drug therapy against leukemia in various settings in preclinical and early phase clinical trials [323–328]. The gene discussed is MTOR; the disease is leukemia.